<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03673995</url>
  </required_header>
  <id_info>
    <org_study_id>PharmarteLtyrosine1</org_study_id>
    <nct_id>NCT03673995</nct_id>
  </id_info>
  <brief_title>Myoinositol Plus L-tyrosine, Selenium and Chromium in PCOS</brief_title>
  <official_title>Use of Myoinositol Plus L-tyrosine, Selenium and Chromium in PCOS Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pharmarte srl</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pharmarte srl</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      PCOS patients were treated every day, with one sachet containing 2000 mg myo-inositol, 500 mg
      L-tyrosine, 40 mcg chromium picolinate, 55 mcg selenium, 200 mcg folic acid. All patients
      underwent, before starting the therapy, after 3 months and 6 months, hormonal evaluation ,
      hirsutism scoring and ovulation assesment. Most of them during the treatment improved their
      symptoms.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 2, 2017</start_date>
  <completion_date type="Actual">October 30, 2018</completion_date>
  <primary_completion_date type="Actual">August 22, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Restore of regular menstrual period</measure>
    <time_frame>6 months of treatment</time_frame>
    <description>Self report</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improving hirsutism</measure>
    <time_frame>6 months of treatment</time_frame>
    <description>Standardised visual scales are preferred when assessing hirsutism, such as the modified Ferriman Gallwey score (mFG) with a level ≥ 4 - 6 indicating hirsutism,</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Restore ovulation</measure>
    <time_frame>6 months of treatment</time_frame>
    <description>Progesterone value in luteal phase</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">186</enrollment>
  <condition>Polycystic Ovary Syndrome</condition>
  <condition>Menstrual Problem</condition>
  <condition>Hirsutism</condition>
  <arm_group>
    <arm_group_label>Myo-inositol+L-tyrosine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One sachet per day containing 2000 mg myo-inositol, 500 mg L-tyrosine, 40 mcg chromium picolinate, 55 mcg selenium, 200 mcg folic acid for improving PCOS symptoms.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Myo-inositol+L-tyrosine</intervention_name>
    <description>PCOS patients were treated every day, with one sachet containing 2000 mg myo-inositol, 500 mg L-tyrosine, 40 mcg chromium picolinate, 55 mcg selenium, 200 mcg folic acid. All patients underwent, before starting the therapy, after 3 months and 6 months, hormonal, hirsutism and ovulation assesment.</description>
    <arm_group_label>Myo-inositol+L-tyrosine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        ° PCOS patients

        Exclusion Criteria:

          -  thyroid dysfunction

          -  hyperprolactinemia

          -  adrenal hyperplasia

          -  patients taking oral contraceptive

          -  any other endocrinological pathologies
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>38 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mario Montanino Oliva, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Altamedica Reproductive Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Altamedica Reproductive Medicine</name>
      <address>
        <city>Roma</city>
        <zip>00198</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>August 22, 2018</study_first_submitted>
  <study_first_submitted_qc>September 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 17, 2018</study_first_posted>
  <last_update_submitted>June 13, 2020</last_update_submitted>
  <last_update_submitted_qc>June 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
    <mesh_term>Hirsutism</mesh_term>
    <mesh_term>Menstruation Disturbances</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inositol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

